Seikagaku will announce the financial results for the Second Quarter of the Fiscal Year ending March 31, 2018 at 16:00 on November 7, 2017.
Annual Report 2017
Ono and Seikagaku Announce Initiation of a Late-Stage Phase II Clinical Trial of SI-613 for Treatment of Enthesopathy
Ono and Seikagaku Reach a Definitive Agreement Related to Co-development and Marketing Collaboration on SI-613 for the Treatment of Osteoarthritis in Japan
Consolidated Financial Results for the First Quarter of Fiscal 2017